Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 6/20 | 0.47 |
| ▸ | CASR | P41180 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631697 | 0.81 | CASR (0.48) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL22169568 | 0.78 | CASR (0.43) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL2609420 | 0.77 | CASR (0.48) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL17239541 | 0.77 | CASR (0.46) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL23862490 | 0.75 | MAPT (0.46) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL20162886 | 0.75 | NOTUM (0.50) | LMNAL3MBTL1 | |
| SCHEMBL8953901 | 0.73 | CASR (0.44) | ELOVL1CASRLMNAMAPTHTT | |
| SCHEMBL12535839 | 0.73 | KDM4C (0.38) | LMNAHTTTSHRRECQLKDM4E | |
| SCHEMBL17239480 | 0.70 | CASR (0.56) | ELOVL1CASRMAPTHTTTSHR | |
| SCHEMBL18191176 | 0.70 | CASR (0.52) | ELOVL1CASRMAPTHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8853202-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853202-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2349273-A1 | MODULATORS OF CXCR7 | ChemoCentryx, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014121-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | ELOVL1 2604/4885CASR 1526/4885LMNA 4842/4885 |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | ELOVL1 2604/4885CASR 1526/4885LMNA 4842/4885 |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | ELOVL1 2604/4885CASR 1526/4885LMNA 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.